Want to see GB:VAL full AI Analyst Report?
VAL Stock Chart & Stats
0.40 p
>-0.01 p(-0.67%)
At close: 4:00 PM EST
0.40 p
>-0.01 p(-0.67%)
Day’s Range― - ―
52-Week Range0.13 p - 0.85 p
Previous CloseN/A
Volume1.58M
Average Volume (3M)1.10M
Market Cap
£2.11M
Enterprise Value180.41K
Total Cash (Recent Filing)£791.61K
Total Debt (Recent Filing)£1.40K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume510,641
30 Day Avg. Volume1,099,814
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Out-licensing Business ModelValiRx’s primary model is to out-license programs and IP, which is durable for early-stage biotechs: it allows the company to progress science while shifting late‑stage development, manufacturing and commercialization costs to partners. Over 2-6 months this reduces capital intensity and preserves strategic optionality to secure milestone-driven financing or non-dilutive partner funding.
Very Low Financial LeverageMinimal recorded debt materially lowers insolvency and interest-rate exposure, giving management flexibility to pursue licensing discussions or raise funds without a heavy interest burden. This structural low-leverage position supports survivability over the coming months while clinical/partnering milestones are pursued.
Focused Therapeutic SpecialtyConcentrating on oncology and women’s health targets areas with persistent unmet medical need and consistent partner interest. This focused pipeline strategy can enhance the firm’s attractiveness to specialized partners and licensors and sustain long-term licensing value independent of short-term market moves.
Bears Say
Persistent Negative Operating Cash FlowSustained operating cash burn indicates the company is not self-funding its R&D and requires external financing or partner deals. Over a 2-6 month horizon this creates urgent runway pressure, raising the likelihood of dilutive equity raises or accelerated partnering on suboptimal terms, which can structurally constrain strategic choices.
Eroding Equity And Shrinking AssetsDeclining equity and assets reflect cumulative losses and reduced balance-sheet capacity. This weakens the company’s negotiating position with partners and lenders, reduces available collateral, and increases the probability of financing on dilutive or expensive terms within the medium term, impairing long-term optionality.
Tiny, Declining Revenue And Persistent LossesRevenue is negligible and fell markedly year-over-year while operating and net losses persist, indicating no near-term path to self-sustaining operations. This structural mismatch between income and cost base means the company must rely on partnering or financing to continue development, a durable risk for the next several months.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.13 p and its highest was 0.85 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £2.11M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Sep 08, 2026 which is in 51 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Jun 22, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.108%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―